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Summary
Background Malignant pleural mesothelioma is almost always fatal, and few treatment options are available. Although 
active symptom control (ASC) has been recommended for the management of this disease, no consensus exists for 
the role of chemotherapy. We investigated whether the addition of chemotherapy to ASC improved survival and 
quality of life.
Methods 409 patients with malignant pleural mesothelioma, from 76 centres in the UK and two in Australia, were 
randomly assigned to ASC alone (treatment could include steroids, analgesic drugs, bronchodilators, palliative 
radiotherapy [n=136]); to ASC plus MVP (four cycles of mitomycin 6 mg/m², vinblastine 6 mg/m², and cisplatin 
50 mg/m² every 3 weeks [n=137]); or to ASC plus vinorelbine (one injection of vinorelbine 30 mg/m² every week for 
12 weeks [n=136]). Randomisation was done by minimisation, with stratiﬁ cation for WHO performance status, 
histology, and centre. Follow-up was every 3 weeks to 21 weeks after randomisation, and every 8 weeks thereafter.
Because of slow accrual, the two chemotherapy groups were combined and compared with ASC alone for the primary 
outcome of overall survival.  Analysis was by intention to treat. This study is registered, number ISRCTN54469112.
Findings At the time of analysis, 393 (96%) patients had died (ASC 132 [97%], ASC plus MVP 132 [96%], ASC plus 
vinorelbine 129 [95%]). Compared with ASC alone, we noted a small, non-signiﬁ cant survival beneﬁ t for ASC plus 
chemotherapy (hazard ratio [HR] 0·89 [95% CI 0·72–1·10]; p=0·29). Median survival was 7·6 months in the ASC 
alone group and 8·5 months in the ASC plus chemotherapy group. Exploratory analyses suggested a survival 
advantage for ASC plus vinorelbine compared with ASC alone (HR 0·80 [0·63–1·02]; p=0·08), with a median survival 
of 9·5 months. There was no evidence of a survival beneﬁ t with ASC plus MVP (HR 0·99 [0·78–1·27]; p=0·95). We 
observed no between-group diﬀ erences in four predeﬁ ned quality-of-life subscales (physical functioning, pain, 
dyspnoea, and global health status) at any of the assessments in the ﬁ rst 6 months.
Interpretation The addition of chemotherapy to ASC oﬀ ers no signiﬁ cant beneﬁ ts in terms of overall survival or 
quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.
Funding Cancer Research UK and the Medical Research Council (UK).
Introduction
Malignant pleural mesothelioma is almost always fatal, 
and the worldwide incidence continues to rise. In the 
UK, the mortality rate increased 12-fold between 1968 
and 2001; nearly 2000 deaths were recorded in 2005, and 
estimates predict that this number will increase to a peak 
of about 2200 by the year 2013.1 By 2001, 25 000 deaths 
had already resulted from mesothelioma in the UK and 
at least another 65 000 are expected by 2050.1 Similar 
ﬁ gures are seen in other western European countries, 
with an estimated 250 000 mesothelioma deaths by 2035.2 
The incidence of mesothelioma is directly related to the 
production and use of asbestos, and whereas the 
incidence peak is approaching in the USA and western 
Europe, in future decades the epidemic will shift towards 
countries that still produce or use large quantities of 
asbestos—eg, Russia, China, Canada, Kazakhstan, 
Brazil, Zimbabwe, India, and Thailand.3
When this present trial was designed in the late 1990s, 
no generally accepted standard treatment for meso-
thelioma existed. The British Thoracic Society (BTS) 
statement for the management of mesothelioma4 
recommended active symptom control (ASC), which 
should involve regular specialist follow-up; structured 
assessment of physical, psychological, and social 
problems; and appropriate treatment, including 
palliative radio therapy and steroids. There was no 
consensus regarding the role of chemotherapy for this 
disease, largely because of the scarcity of randomised 
trials. Several small, non-randomised studies of various 
single-drug and multidrug regimens had been 
undertaken, and Ryan and colleagues’ review of such 
studies including 15 or more patients5 concluded that 
various single agents had shown temporary, partial 
response rates of around 20%; furthermore, there was 
no evidence that drug combinations were better than 
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single agents. Ryan and colleagues5 also commented 
that, because of the diﬀ use nature of this tumour, 
response was diﬃ  cult to measure, and choosing 
regimens on the basis of response rates might not be 
the best surrogate for survival beneﬁ t.
Since most patients with malignant pleural meso-
thelioma present with many symptoms, relief or control 
of these symptoms is a key factor and therefore a 
worthwhile criterion for selection of treatment. However, 
at the time that this trial was designed, good published 
data derived from quality-of-life questionnaires 
completed by the patient were only available for two 
regimens: the three-drug combination of mitomycin, 
vinblastine, and cisplatin (MVP); and single-agent 
vinorelbine. Middleton and colleagues6 treated 
39 patients with six cycles of MVP (mitomycin 8 mg/m², 
vinblastine 6 mg/m², and cisplatin 50 mg/m²), with all 
drugs given on day 1 of a 21-day cycle (mitomycin was 
omitted from cycles three and ﬁ ve). The regimen was 
well tolerated, and 62% patients reported an overall 
improvement in their symptoms (including 
79% reporting reduced pain and 67% reduced cough). 
Steele and colleagues7 treated 29 patients with single-
agent vinorelbine 30 mg/m² every 7 days until disease 
progression, and assessed quality of life with the 
Rotterdam Symptom Checklist.8 The regimen was well 
tolerated, and although 62% of patients had grade 3 or 4 
neutropenia, only one had neutropenic sepsis. 48% of 
patients reported improved respiratory symptoms and 
76% improved psychological functioning.
Following encouraging results from a feasibility study 
to assess whether patients would consent to be 
randomised into a trial with ASC alone as one of the 
groups,9 our three-group randomised trial sought to 
compare ASC alone with ASC plus MVP and ASC plus 
vinorelbine in terms of survival, symptom control, toxic 
eﬀ ects, quality of life, tumour response, and 
progression.
Methods
Patients and study design
In this multicentre randomised controlled trial, patients 
with recently diagnosed malignant pleural mesothelioma 
were enrolled from 76 centres in the UK and two in 
Australia between Sept 17, 2001, and July 31, 2006. 
Eligible patients could have had a previous surgical 
resection for mesothelioma (provided that a CT scan 
showed residual stable or progressive disease) or local 
radiotherapy to an exploratory thoracotomy wound site, 
but no previous chemotherapy. Patients had to be ﬁ t for 
chemotherapy (WHO performance status 0–2, with 
normal blood counts, creatinine clearance >50 mL per 
min, and any symptomatic pleural eﬀ usion brought 
under control), and have no other disease or previous 
malignancy that was likely to interfere with the protocol 
treatments or comparisons.
All patients provided written informed consent and 
the local ethics committee approved the protocol. An 
independently led trial steering committee was 
appointed to oversee its execution, and an independent 
data monitoring committee reviewed the interim data at 
regular, usually yearly, meetings. No formal stopping 
rules were used.
Procedures
An independent reference histopathologist (AGN) was 
available to be consulted about any diagnostic or 
histopathological queries, and from September 2003, 
tumour samples were sent to him to check the accuracy 
of diagnosis. Blood samples were also gathered and sent 
to a central repository.
Treatment centres telephoned the MRC Clinical Trials 
Unit (London, UK) who randomly allocated patients 
using a minimisation process, with stratiﬁ cation for 
WHO performance status, histology, and centre, to 
receive ASC alone, ASC plus MVP, or ASC plus 
vinorelbine. The essential elements of ASC were deﬁ ned 
as regular follow-up in a specialist clinic; structured 
physical, psychological, and social assessments at every 
clinic visit; rapid involvement of additional specialists; 
and parallel nursing support. Patients could receive, as 
required, steroids, analgesic drugs, appetite stimulants, 
bronchodilators, or palliative radiotherapy.
Patients in the ASC plus MVP group were prescribed 
four cycles of MVP (mitomycin 6 mg/m², vinblastine 
6 mg/m² [max 10 mg], and cisplatin 50 mg/m²) all given 
on day 1 of a 21-day cycle, in addition to ASC. The protocol 
recommendation was that patients should receive 
antiemetic drugs and dexamethasone. Patients in the 
409 patients randomised
136 assigned to ASC 137 assigned to ASC+MVP 136 assigned to ASC+V
132 died
4 alive
132 died
5 alive
129 died
7 alive
136 analysed for primary
outcome of overall
survival
137 analysed for primary
outcome of overall
survival
136 analysed for primary
outcome of overall
survival
Chemotherapy received:
4 received 0 cycles
31 received 1–3 cycles
26 received 4–6 cycles
7 received 7–9 cycles
68 received 10–12 cycles
Chemotherapy received:
5 received 0 cycles
11 received 1 cycle
16 received 2 cycles
16 received 3 cycles
85 received 4 cycles
4 data outstanding
Figure 1: Trial proﬁ le
After 3 years accrual, the trial design was changed to a two-group comparison by combining the two chemotherapy 
groups. The three-way randomisation was retained to allow some exploratory analyses of the two diﬀ erent 
chemotherapy groups. ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine. 
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ASC plus vinorelbine group were prescribed one injection 
of vinorelbine (Laboratoires Pierre Fabre, Catres, 
Toulouse, France) every week for 12 weeks (30 mg/m² 
[max 60 mg]) in addition to ASC, with a 2-week gap 
between injections six and seven.
The recommendation was that chemotherapy should 
start as soon as possible after randomisation. Detailed 
dose modiﬁ cations for each regimen were listed in the 
protocol, but generally, patients only received 
chemotherapy if they had an adequate blood count 
(total white blood cell count >3000 cells per μL, 
neutrophils >1500 cells per μL, and platelets 
>100 000 cells per μL) and if there was no clinical 
evidence of infection. For patients allocated to ASC plus 
MVP, the criteria also included no renal toxic eﬀ ects, 
severe constipation, or ototoxicity. In the management 
of haematological toxic eﬀ ects (and hepatic toxic eﬀ ects 
in the ASC plus vinorelbine group), the protocol 
recommendation was that chemotherapy be delayed for 
1 week, and the patient then be reassessed. Clinicians 
were free to provide non-protocol treatment at any stage 
if it was felt to be in the patient’s best interest, although 
such patients remained in the trial for follow-up and 
analysis.
Local research staﬀ  completed reports to cover the 
baseline assessment (before randomisation), pathology, 
chemotherapy (if allocated), and follow-up (every 3 weeks 
to 21 weeks after randomisation, and then every 8 weeks 
thereafter). Reports included details of treatment, blood 
counts and other relevant tests, tumour response, 
performance status, and details of symptoms or adverse 
events. We formally assessed tumour response by CT 
scan at 15 weeks using RECIST (Response Evaluation 
Criteria in Solid Tumors) criteria10 modiﬁ ed (as suggested 
by Byrne and co-workers11) because of the diﬀ use nature 
of meso thelioma, measuring the thickness of 
circumferential pleural tumour at three or more separate 
levels on transverse sections.
We asked patients to complete the EORTC (European 
Organization for Research and Treatment of Cancer) 
core quality-of-life questionnaire (QLQ-C30)12 and the 
lung cancer module (LC13)13 at baseline and at every 
subsequent assessment. Since one of the main aims of 
treatment was the control of common presenting 
symptoms (particularly chest pain, breathlessness, 
malaise, and sweating), and since the EORTC question-
naires did not include an item on sweating, this 
additional question was added.
Statistical analysis
The primary outcome measure was overall survival; 
secondary outcome measures were symptom control, 
ASC 
(N=136)
ASC+MVP 
(N=137)
ASC+V 
(N=136)
Median age (years [range]) 65 (47–85) 65 (46–82) 65 (49–83)
Men 125 (92%) 124 (91%) 122 (90%)
Histology
Epithelial 99 (74%) 100 (74%) 98 (73%)
Biphasic/mixed 11 (8%) 13 (10%) 17 (13%)
Other 24 (18%) 22 (16%) 19 (14%)
Not reported 2 2 2
WHO performance status
0 31 (23%) 32 (23%) 30 (22%)
1 87 (64%) 86 (63%) 86 (63%)
2 18 (13%) 19 (14%) 20 (15%)
IMIG stage
I/II 24 (21%) 32 (28%) 27 (23%)
III 37 (33%) 30 (26%) 39 (34%)
IV 51 (46%) 54 (47%) 50 (43%)
Not reported 24 21 20 
Analgesic drugs
None 27 (21%) 37 (27%) 34 (25%)
Non-opiates 46 (35%) 44 (32%) 44 (32%)
Moderate opiates 38 (29%) 32 (24%) 37 (27%)
Strong opiates 19 (15%) 23 (17%) 21 (15%)
Not reported 6 1 0
Median time from diagnosis 
to randomisation (days [IQR])
58 (35–80) 61 (36–85) 63 (43–87)
Data are number (%) unless otherwise speciﬁ ed. ASC=active symptom control. 
MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine. IMIG=International 
Mesothelioma Interest Group.
Table 1: Baseline patient characteristics
ASC (N=136) ASC+MVP 
(N=137)
ASC+V 
(N=136)
As reported by clinicians
Lethargy 26/132 (20%) 37/135 (27%) 32/134 (24%)
Chest pain 36/132 (27%) 29/135 (21%) 28/133 (21%)
Sweating 22/132 (17%) 16/135 (12%) 19/133 (14%)
Anorexia 18/132 (14%) 20/135 (15%) 17/134 (13%)
Cough 15/132 (11%) 19/135 (14%) 17/133 (13%)
Constipation 17/132 (13%) 18/135 (13%) 13/134 (10%)
Other pain 14/130 (11%) 11/134 (8%) 20/132 (15%)
MRC grade 4+ 
breathlessness*
44/128 (34%) 41/131 (31%) 38/133 (29%)
As reported by patients with the QOL questionnaire
Shortness of breath 49/126 (39%) 46/126 (37%) 42/124 (34%)
Tiredness 45/126 (36%) 37/125 (30%) 37/122 (30%)
General pain 43/127 (34%) 35/127 (28%) 32/124 (26%)
Worried 37/126 (29%) 22/127 (17%) 23/123 (19%)
Chest pain 31/125 (25%) 28/127 (22%) 21/124 (17%)
Cough 28/126 (22%) 26/128 (20%) 23/125 (18%)
Sweating 23/106 (22%) 19/114 (17%) 24/110 (22%)
Constipation 29/127 (23%) 26/127 (20%) 18/124 (15%)
ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. 
V=vinorelbine. QOL=quality of life. *Scored as follows: MRC grade: 1=climbs hills 
or stairs without dyspnoea; 2=walks any distance on the ﬂ at without dyspnoea; 
3=walks over 100 m without dyspnoea; 4=dyspnoea on walking 100 m or less; 
5=dyspnoea on mild exertion—eg, undressing; 6=dyspnoea at rest.
Table 2: Moderate or severe symptoms at baseline
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toxic eﬀ ects, quality of life, tumour response, and 
progression.
With an estimated median survival in the control 
group (ASC alone) of 9 months, the trial was designed 
to detect an improvement of 3 months (ie, to 12 months) 
in the ASC plus MVP and ASC plus vinorelbine groups. 
A total of 840 patients (280 in each group) was needed 
to detect this diﬀ erence, with 512 events (deaths) in 
both comparisons (ASC vs ASC plus MVP, and 
ASC vs ASC plus vinorelbine) with 5% signiﬁ cance and 
90% power. This number of patients was also considered 
suﬃ  cient to reliably detect diﬀ erences of half a standard 
deviation between ASC and the two chemotherapy 
groups in terms of symptom control and quality of life, 
with 90% power. We aimed to accrue patients within 
4 years.
Analysis was by intention to treat. Duration of survival 
was calculated from the date of randomisation to the 
date of death from any cause, with survivors being 
censored at the date that they were last known to be 
alive. We calculated progression-free survival from the 
date of randomisation to the date of ﬁ rst progression, 
recurrence, or death, whichever was soonest. Patients 
alive and progression free were censored at the date that 
they were last known to be alive and free of progression. 
We used hazard ratios to compare overall survival. 
Comparisons of symptom control, performance status, 
use of analgesic drugs, quality of life, toxic eﬀ ects, and 
response were tested with the Kruskal-Wallis or 
Mann-Whitney test. We used the χ² test to test for 
interactions involving binary and categorical variables, 
and the test for interaction for continuous data. All p 
values are two sided.
Changes to the trial design
Accrual to this trial began in September 2001, although 
the 34 patients who had been randomly assigned 
between all three groups in the feasibility trial were also 
included. However, by January 2004, only 232 patients 
had been entered, and it was clear that the target number 
of patients was not going to be reached in a timely 
manner. The trial design was therefore changed to a 
two-group comparison by combining the two 
chemotherapy groups, although the three-way ran-
domisation was retained to allow some exploratory 
analyses of the two diﬀ erent chemotherapy groups. The 
two-group design needed a total of 420 patients (140 ASC, 
280 ASC plus chemotherapy) and 380 events (deaths) to 
reliably detect an improvement from 9 months median 
survival with ASC alone to 12 months with ASC plus 
chemotherapy (5% signiﬁ cance level, 76% power). Since 
accrual decreased through 2005, a closure date of 
July 31, 2006, was set.
This study is registered, number ISRCTN54469112.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for 
publication. 
Results
Figure 1 shows the trial proﬁ le. The number of patients 
who were screened for eligibility was not recorded. 
409 patients were enrolled, and only two patients (who 
moved abroad) have been lost to follow-up. 136 patients 
were assigned to ASC, 137 to ASC plus MVP, and 136 to 
ASC plus vinorelbine. The three treatment groups were 
well matched for all characteristics at baseline (table 1). 
The median age of patients was 65 years (range 46–85), 
371 (91%) were men, and 352 (86%) had a WHO 
N Improved Controlled Prevented Palliated*  p value†
Lethargy
ASC 110 4 (4%) 33 (35%) 18 (19%) 55 (50%)
ASC+MVP 122 11 (9%) 22 (18%) 22 (18%) 55 (45%) 0·54
ASC+V 119 8 (7%) 17 (14%) 18 (15%) 43 (36%) 0·047
Chest pain
ASC 111 8 (7%) 23 (21%) 23 (21%) 54 (49%)
ASC+MVP 122 13 (11%) 37 (30%) 35 (29%) 85 (70%) 0·0017
ASC+V 117 12 (10%) 29 (25%) 32 (27%) 73 (62%) 0·051
Sweating
ASC 111 5 (5%) 21 (19%) 46 (41%) 72 (65%)
ASC+MVP 122 11 (9%) 21 (17%) 66 (54%) 98 (80%) 0·012
ASC+V 117 7 (6%) 16 (14%) 59 (50%) 82 (70%) 0·48
Anorexia
ASC 111 8 (7%) 16 (14%) 48 (43%) 72 (65%)
ASC+MVP 122 7 (6%) 18 (15%) 61 (50%) 86 (70%) 0·44
ASC+V 117 8 (7%) 14 (12%) 55 (47%) 77 (66%) 0·99
Cough
ASC 111 11 (10%) 27 (24%) 30 (27%) 68 (61%)
ASC+MVP 121 14 (12%) 35 (29%) 37 (31%) 86 (71%) 0·15
ASC+V 117 10 (9%) 33 (28%) 38 (32%) 81 (69%) 0·26
Constipation
ASC 111 7 (6%) 11 (10%) 56 (50%) 74 (67%)
ASC+MVP 122 11 (9%) 10 (8%) 61 (50%) 82 (67%) 0·96
ASC+V 119 6 (5%) 23 (19%) 62 (52%) 91 (76%) 0·13
Other pain
ASC 110 4 (4%) 20 (18%) 41 (37%) 65 (59%)
ASC+MVP 122 8 (7%) 24 (20%) 54 (44%) 86 (70%) 0·093
ASC+V 118 11 (9%) 21 (18%) 43 (36%) 75 (64%) 0·58
Breathlessness
ASC 107 9 (8%) 16 (15%) 6 (6%) 31 (29%)
ASC+MVP 118 11 (9%) 16 (14%) 9 (8%) 36 (31%) 0·92
ASC+V 113 10 (9%) 14 (12%) 9 (8%) 33 (29%) 0·91
ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine. *Patients who had died by 
3 months were considered not palliated. †χ2 test compared with ASC. ‡Improved: moderate or severe at baseline, mild 
or nil at 3 months; controlled: mild at baseline, mild or nil at 3 months; and prevented: nil at baseline, nil at 3 months.
Table 3: Symptom palliation at 3 months‡
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performance status of 0 or 1. 297 (74%) of 403 patients 
were considered by the local histopathologist to have 
epithelial histology. The median time from diagnosis to 
randomisation was 60 days (IQR 37–85) and most 
patients had disease of International Mesothelioma 
Interest Group stage III14 (106 [31%] of 344) or stage IV 
(155 [45%] of 344). Additionally, 107 (27%) of 402 were 
already on moderate opiates and 63 (16%) of 402 on 
strong opiates. Patients presented with several symptoms 
(table 2), and 123 (31%) of 392 had dyspnoea walking 
100 m or less. Data from the quality-of-life questionnaires 
completed by the patient reﬂ ected symptoms reported by 
clinicians, with the commonest moderate or severe 
symptoms relating to shortness of breath, tiredness, and 
pain (table 2). Consequently, patients reported poor 
physical functioning (eg, 181/375 [48%] having diﬃ  culties 
taking a long walk), limited leisure and social activities, 
and reduced overall quality of life.
Of the 193 patients who were randomly assigned after 
instigation of collection of samples for histological 
review, 135 consented to donate their tumour samples; 
however, three patients had only cytology preparations 
and 27 samples were unobtainable. Thus 105 cases with 
anonymised histology reports and slides or blocks were 
sent for review, of which 103 were conﬁ rmed as 
mesothelioma. In two cases, immunochemistry failed 
to identify a phenotype for deﬁ nitive diagnosis, but 
samples contained epithelial or biphasic malignancy 
that was consistent with mesothelioma and were 
classiﬁ ed as such after clinical-pathological review.
85 (64%) of 133 patients received the prescribed four 
cycles of MVP. A further 16 (12%) received three cycles, 
16 (12%) two cycles, and 11 (8%) one cycle. Only ﬁ ve (4%) 
patients who were allocated to ASC plus MVP did not 
receive any protocol chemotherapy (one patient refused, 
two progressed, one died before starting, and one was 
given carboplatin, rather than cisplatin, because of 
tinnitus). The information about the treatment received 
for the remaining four patients is outstanding. Of the 
128 patients who received MVP, 47 (37%) had some 
delays (>28 days between cycles) and 67 (52%) had a 
dose modiﬁ cation (>10% dose change). 
Of the 136 patients who were prescribed one injection 
of vinorelbine every week for 12 weeks, 68 (50%) received 
between ten and 12 injections, seven (5%) between 
seven and nine injections, 26 (19%) between four and 
six injections, and 31 (23%) between one and three 
injections. Only four (3%) received no protocol chemo-
therapy (two refused, two died before starting). Of the 
132 patients who started vinorelbine, 104 (79%) had a 
delay (>10 days between injections) and 48 (36%) a 
modiﬁ cation (>10% dose change). The main problem 
was neutropenia (26/63 [41%] patients having grade 3+ 
neutropenia after this speciﬁ c question was added to the 
case report forms), although only eight (6%) patients 
were reported as stopping prematurely because of 
haematological toxic eﬀ ects.
Only 140 patients (84 ASC plus MVP, 56 ASC plus 
vinorelbine) had a formal tumour assessment after the 
course of chemotherapy, of whom only eight (10%) in 
the ASC plus MVP group and nine (16%) in the ASC 
plus vinorelbine group had a response to protocol 
chemo therapy. A further 52 (62%) patients in the ASC 
plus MVP group and 33 (59%) in the ASC plus 
vinorelbine group had stable disease. Because of the 
diﬃ  culty of assessing response in this disease, clinicians 
were also asked at 15 weeks after randomisation whether, 
in their opinion, the tumour had improved, stayed the 
same, or worsened. We assessed a total of 369 patients 
(118 ASC, 124 ASC plus MVP, and 127 ASC plus 
vinorelbine) in this way and 91 patients (16 [14%] ASC, 
36 [29%] ASC plus MVP, and 39 [31%] ASC plus 
vinorelbine) were reported to have improved at this 
time. 87 (74%) patients in the ASC group, 80 (65%) in 
the ASC plus MVP group, and 78 (61%) in the ASC plus 
vinorelbine group were reported as stable.
Pr
op
or
tio
n 
w
ith
 m
od
er
at
e 
or
 se
ve
re
 sy
m
pt
om
Pr
op
or
tio
n 
w
ith
 m
od
er
at
e 
or
 se
ve
re
 sy
m
pt
om
Time from randomisation (months)
0 1 2 3 4 5 6  
ASC
ASC+MVP
ASC+V
0
0·1
0·2
0·3
0·4
0·5
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0·8
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0·6
0·7
0·8
0·9
1·0
A    Moderate or severe chest pain
B    Moderate or severe lethargy
Figure 2: Clinicians assessment of symptoms and side-eﬀ ects
(A) Proportion of patients with moderate or severe chest pain. (B) Proportion of patients with moderate or severe 
lethargy. Error bars indicate 95% CIs. ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. 
V=vinorelbine.
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Clinicians reported the occurrence and severity of 
16 key symptoms at every assessment (table 3). One 
deﬁ nition of palliation is that moderate or severe 
symptoms at baseline should be improved, mild 
symptoms should be controlled, and other symptoms 
prevented from occurring.15 With these criteria, we 
undertook exploratory analyses to compare changes 
from baseline to 3 months of the eight commonest 
symptoms reported at baseline (table 3).
The only symptoms for which there seemed to be 
evidence of palliation were noted with the MVP regimen 
for chest pain (ASC plus MVP vs ASC, p=0·0017) and 
sweating (ASC plus MVP vs ASC, p=0·012) (table 3). 
Nevertheless, as expected, patients had chemotherapy 
side-eﬀ ects, although the only comparisons showing 
evidence of increased side-eﬀ ects were alopecia (ASC 
plus MVP [six of 117] vs ASC [none of 95], p=0·025; ASC 
plus vinorelbine [six of 108] vs ASC [none of 95], 
p=0·020), lethargy (ASC plus vinorelbine [49/109] vs 
ASC [28/95], p=0·023), and haematological toxic eﬀ ects, 
which were only collected in the latter half of the trial 
(ASC plus MVP [eight of 60] vs ASC [none of 50], 
p=0·007; ASC plus vinorelbine [18/50] vs ASC [none 
of 50], p<0·0001). However, when we repeated these 
analyses at 6 months we recorded no signiﬁ cant 
diﬀ erences between treatments. Patterns of symptoms 
and side-eﬀ ects can be seen by plotting the proportion 
of patients with moderate or severe symptoms over 
time, and ﬁ gure 2 shows histograms for chest pain and 
lethargy.
The number of patients completing the EORTC 
questionnaires (as a proportion of the number alive at 
the various timepoints) fell from 381 (93%) at baseline 
(ASC 127 [93%] of 136, ASC plus MVP 129 [94%] of 137, 
ASC plus vinorelbine 125 [92%] of 136), to 280 (75%) at 
3 months (ASC 88 [74%] of 119, ASC plus MVP 100 [78%] 
of 129, ASC plus vinorelbine 92 [73%] of 126) and 
175 (58%) at 6 months (ASC 56 [62%] of 90, ASC plus 
MVP 46 [46%] of 101, ASC plus vinorelbine 73 [67%] 
of 109). Reduced levels of completion (usually due to 
questionnaires not being handed out or patients being 
too unwell to complete them) make analyses diﬃ  cult, 
since whether data are missing at random (and thus 
could be imputed) or not (and thus could bias the 
comparison) is unclear. Equally, many statistical 
comparisons (eg, testing between every treatment at 
each timepoint) can produce false positive results, and 
could lead to misinterpretation. Consequently, simple 
descriptive plots showing patterns over time and 
absolute changes can usually be most informative. The 
EORTC QLQ-C30 can be de-aggregated into ﬁ ve 
functional and nine symptom scales, as well as a score 
for global heath status. Figure 3 shows histograms of 
the mean standardised scores for the four predeﬁ ned 
quality-of-life endpoints (physical functioning, pain, 
dyspnoea, and global health status), indicating little 
change in any of these subscales over time or between 
treatments. The addition of chemotherapy therefore 
seemed to have no major overall positive or negative 
eﬀ ect on quality of life.
Most patients (218 [53%]) received no extra anticancer 
treatment. Much the same numbers of patients in the 
Figure 3: Mean standardised scores for the four predeﬁ ned quality-of-life 
endpoints
(A) Physical functioning; (B) pain; (C) dyspnoea; and (D) global quality of life. 
Error bars indicate 95% CIs. ASC=active symptom control. MVP=mitomycin, 
vinblastine, and cisplatin. V=vinorelbine. 
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three groups received additional chemotherapy 
(ASC 21 [15%], ASC plus MVP 23 [17%], and ASC plus 
vinorelbine 14 [10%]), although only 15 patients (ASC 
seven, ASC plus MVP six, ASC plus vinorelbine two) 
received pemetrexed. More patients assigned to ASC 
alone than to chemotherapy groups received radiotherapy 
(ASC 37 [27%], ASC plus MVP 21 [15%], ASC plus 
vinorelbine 26 [19%]) and measures to control pleural 
eﬀ usion (ASC 20 [15%], ASC plus MVP 12 [9%], ASC 
plus vinorelbine 11 [8%]). During the course of the trial, 
263 patients (ASC 97 [71%], ASC plus MVP 78 [57%], 
ASC plus vinorelbine 88 [65%]) needed increased doses 
of analgesic drugs.
At the time of analysis, 393 (96%) patients had died 
(ASC 132 [97%], ASC plus MVP 132 [96%], ASC plus 
vinorelbine 129 [95%]), and the median follow-up of the 
16 survivors was 36·4 months (IQR 13·2–50·2). Five 
patients (three ASC plus MVP, two ASC plus vinorelbine) 
were still alive more than 4 years after randomisation. 
The cause of death was reported to be mesothelioma in 
365 patients (ASC 127 [96%], ASC plus MVP 122 [92%], 
ASC plus vinorelbine 116 [90%]). One patient in the ASC 
plus vinorelbine group was considered to have had a 
treatment-related death, although treatment was 
regarded as a contributory factor in a further three 
patients in the ASC plus MVP group and nine in the ASC 
plus vinorelbine group.
Figure 4 shows the overall survival for ASC plus 
chemotherapy versus ASC alone. We noted a small but 
non-signiﬁ cant beneﬁ t for patients in the ASC plus 
chemo therapy group (hazard ratio [HR] 0·89 [95% CI 
0·72–1·10]; p=0·29). In the ASC alone group, the 
estimated median survival was 7·6 months and and 29% 
of patients were alive at 1 year. Application of the HR to 
these ﬁ gures resulted in a median survival of 8·5 months 
and 1-year survival of 32% for the ASC plus chemotherapy 
group. In exploratory analyses (ﬁ gure 4), patients in the 
ASC plus vinorelbine group had a longer overall survival 
than did those in the ASC alone group (HR 0·80 
[0·63–1·02]; p=0·08), which was equivalent to a 2-month 
absolute increase in median survival (from 7·6 months 
with ASC to 9·5 months with ASC plus vinorelbine), 
although we noted no evidence of a beneﬁ t with ASC 
plus MVP (HR 0·99 [0·78–1·27]; p=0·95). A comparison 
of the two chemotherapy groups directly gave an HR 
of 0·77 (95% CI 0·61–0·99; p=0·04), suggesting a beneﬁ t 
of vinorelbine compared with MVP.
141 patients (ASC 49 [36%], ASC plus MVP 46 [34%], 
ASC plus vinorelbine 46 [34%]) were reported as having 
pro gressive disease and 402 as having either progressed 
or died (ASC 134 [99%], ASC plus MVP 136 [99%], ASC 
plus vinorelbine 132 [97%]). Overall, we noted a small 
but non-signiﬁ cant beneﬁ t for chemotherapy in 
progression-free survival (HR 0·91 [95% CI 0·74–1·12]; 
p=0·39), giving a median progression-free survival of 
5·1 months for ASC and 5·6 months for ASC plus 
chemotherapy, and 1-year progression-free survival of 22% 
and 25%, respectively. We observed no evidence of a 
beneﬁ t in progression-free survival for patients in the 
ASC plus MVP group (HR 1·01 [0·79–1·28]; p=0·96), 
but we noted a non-signiﬁ cant beneﬁ t with ASC plus 
vinorelbine (HR 0·82 [0·65–1·05]; p=0·114; ﬁ gure 5). 
Application of the HR to the ASC values gives a median 
progression-free survival of 5·1 months and a 1-year 
progression-free survival of 22% for ASC plus MVP, and 
6·2 months and 28%, respectively, for ASC plus 
vinorelbine.
To explore whether there was any evidence that 
subgroups of patients (deﬁ ned by the baseline 
characteristics in table 1) beneﬁ ted more or less from 
chemotherapy, univariate predictive analyses were 
undertaken (table 4). We saw no clear evidence that any 
subgroup of patients beneﬁ ted more or less from 
chemotherapy.
Figure 4: Overall survival
(A) Two-group comparison: ASC vs ASC plus chemotherapy. (B) Three-group comparison: ASC vs ASC plus MVP vs 
ASC plus vinorelbine. ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine. 
CT=chemotherapy.
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Discussion
In this large randomised controlled trial in mesothelioma, 
we identiﬁ ed no signiﬁ cant survival beneﬁ t from the 
addition of chemotherapy to ASC, and no evidence of a 
diﬀ erence in quality of life. However, exploratory analyses 
suggest that vinorelbine needs further investigation. 
Clinicians and patients can now make better informed 
decisions about advantages and disadvantages of 
chemotherapy and can discuss the balance of possible 
survival gain against the inconvenience and toxic eﬀ ects 
of treatment, which is especially important in view of the 
increasing median age of patients presenting with 
malignant mesothelioma.
This study was launched with the aim of accruing 
840 patients with malignant mesothelioma in a 
three-group trial to assess the value of both MVP and 
vinorelbine compared with ASC alone, on the basis of 
phase II data showing good symptom control with these 
two chemotherapy regimens. Trials that incorporate an 
ASC group are diﬃ  cult to recruit to, and despite a 
feasibility study suggesting that about half of the patients 
would accept such a randomisation,9 accrual was slower 
than was required, and the design had to revert to the 
more generic comparison of ASC versus ASC plus 
chemotherapy to accommodate a smaller sample size.
There seemed to be two main reasons for the slow 
accrual. First, the results of a large randomised trial 
showing a modest survival advantage (2·8 months, HR 
0·77, p=0·020) for cisplatin and pemetrexed, compared 
with cisplatin alone, were presented at the American 
Society for Clinical Oncology yearly meeting in 2002.16 
Subsequently, many UK patients who were ﬁ t for 
chemotherapy received this combination, or carboplatin 
and pemetrexed, as part of the expanded access 
programme that was undertaken by the company 
making pemetrexed. Approaches to the drug company 
to include the cisplatin and pemetrexed regimen in our 
trial were unsuccessful. Second, some patients simply 
did not want any chemotherapy, as conﬁ rmed by a study 
in Leeds17 that audited all referred mesothelioma cases 
between 2002 and 2005; of 54 patients who were ﬁ t for, 
and oﬀ ered, chemotherapy, 28 (52%) declined it. The 
results of our trial suggest that some patients receiving 
ASC alone can do surprisingly well. Patients allocated 
ASC alone generally had good symptom control and of 
course avoided the toxic eﬀ ects related to chemotherapy, 
resulting in overall quality of life which was very 
comparable to that of patients receiving chemotherapy.
However, despite the importance of quality of life, 
collection of good longitudinal data is a challenge in 
populations with short survival, and our compliance 
dropped to less than 60% of patients surviving at 
6 months, which is a proportion not uncommon in trials 
of patients with advanced non-small cell lung cancer.18 
Improving on these levels of compliance needs 
substantial ﬁ nancial, organisational, and training 
resources.19
Nevertheless, the results of our trial suggest that 
chemotherapy is feasible and acceptable, although the 
survival beneﬁ t might be small, perhaps increasing 
median survival by about 1 month. Although more than 
400 patients were enrolled, this number was insuﬃ  cient 
to make reliable conclusions about the two diﬀ erent 
chemotherapy regimens used. However, despite patients 
in the vinorelbine group having more neutropenia and 
receiving less of their prescribed course of treatment, 
they seemed to have similar response rates and symptom 
control to those receiving MVP, but possibly better 
survival.
Therefore, in a disease with few therapeutic options, 
vinorelbine certainly deserves further investigation. One 
disadvantage of this regimen is the weekly schedule, 
although now that oral vinorelbine is available, and 
considered to be equivalent to intravenous administra-
tion in non-small cell lung cancer,20 a weekly regimen 
becomes much more viable than it previously was, and 
would be an attractive alternative for patients.
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Figure 5: Progression-free survival
ASC=active symptom control. MVP=mitomycin, vinblastine, and cisplatin. V=vinorelbine.
Type of analysis p value 
ASC vs ASC+CT ASC vs ASC+V
Age Continuous 0·18 0·21
Sex Category (men, women) 0·10 0·22
Histology Category (epithelial, other) 0·087 0·10
WHO PS Trend (PS0, PS1, PS2) 0·83 0·43
IMIG stage Trend (I/II, III, IV) 0·15 0·18
Analgesic drugs Trend (none, non-opiates, 
moderate opiates, strong opiates)
0·083 0·062
Time from diagnosis to randomisation Continuous 0·29 0·59
ASC=active symptom control. CT=chemotherapy. V=vinorelbine. PS=performance status. IMIG=International 
Mesothelioma Interest Group.
Table 4: Predictive factors (exploration of interactions between treatment and baseline patients’ 
characteristics)
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Our trial needs to be considered in the context of the 
two other large randomised trials in this disease. In the 
Vogelzang trial,21 456 patients were randomly assigned 
to receive cisplatin alone or cisplatin plus pemetrexed. 
The combination group had a median survival of 
12·1 months compared with 9·3 months for patients in 
the cisplatin-alone group (HR 0·77, p=0·02). 
Van Meerbeeck and colleagues22 randomly assigned 
250 patients to cisplatin alone or cisplatin plus 
raltitrexed. The median survival was 11·4 months for 
the combination group compared with 8·8 months for 
cisplatin alone (HR 0·76 [95% CI 0·58–1·00], p=0·048).
Thus the three large randomised trials undertaken so 
far suggest that pemetrexed, raltitrexed, and vinorelbine 
could have a role in this disease, but they do not clarify 
the role of platinum. Ellis and colleagues’ review23 
suggested that cisplatin had the highest response rate of 
all single agents, although this rate was only 20% and 
based on only 108 patients. In the two trials21,22 in which 
cisplatin (75–80 mg/m²) was used as the control, the 
median survival rates were 8·8 months and 9·3 months, 
compared with 7·6 months for ASC in our trial. This 
ﬁ nding might or might not show the eﬃ  cacy of cisplatin, 
since there is a great danger in comparing across trials, 
and this diﬀ erence could well have been due to diﬀ erent 
methods of patient selection in the three trials. 
Nevertheless, the relative failure of the cisplatin-based 
treatment in our trial (MVP) was unexpected. It could 
have been because we used only cisplatin 50 mg/m² or 
stopped after four cycles (rather than continue to 
progression). One UK centre has recently updated their 
experience with MVP24 and reported a similarly 
disappointing outcome with a fairly low median survival 
(7 months) despite good symptomatic improvement.
Clariﬁ cation of the role of platinum in this disease is a 
priority, since the age of the cohort of patients most at 
risk of developing mesothelioma in the UK and Europe 
is increasing inexorably. This cohort is composed of 
men born between 1945 and 1950,2 which thus 
corresponds to a median age at presentation of 55–60 
years in 2005, of 70–75 years in 2020, and 80–85 years in 
2030. Thus now, and especially in the future, we will 
need to direct our research at treatments that are 
applicable and acceptable to an elderly (and over the 
next few years, a very elderly) group of patients, who 
might not be suitable for cisplatin-based chemotherapy.
Where do we go from here? Pemetrexed is the only 
licensed compound for the treatment of mesothelioma 
in the UK.23 The results of our trial suggest that 
vinorelbine might be eﬀ ective, but non-inferiority trials 
(which typically include many more patients than the 
largest superiority trials reported so far) would be virtually 
impossible to undertake in this disease. One option 
might be to try to incorporate vinorelbine with cisplatin 
and pemetrexed (either concurrently or sequentially), but 
as with most cancers, the emergence of many new agents 
and targeted treatment might hold most promise.25
See Online for webappendix
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